Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-817399 plus methotrexate in moderate to severe rheumatoid arthritis with inadequate response to methotrexate
2011-002024-40Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BMS-817399 in rheumatoid arthritis (RA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary efficacy endpoint. Started Oct 2011; status: completed.
02
Drugs
BMS-817399
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-002024-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002024-40.